I. Pioneer a new approach for drug target discovery that has implications for a broad range of developmental and chronic illnesses. II. Develop a robust technology platform for large-scale targeted genomic engineering to enable more complete recapitulation of human disease genotypes in animal models. We will enable precise introduction of combinations of disease-associated genetic mutations into a single animal model. III. Develop a technology for targeted epigenome modification to enable direct functional testing of causal links between specific epigenetic modifications and disease pathophysiology. IV. Identify fundamentally new classes of therapeutics for major depression.

Public Health Relevance

Major depressive disorder is a devastating mental illness affecting millions of Americans annually, with a large fraction of patients unresponsive to available therapies. The proposed project aims to identify fundamentally new classes of therapeutics by probing the epigenetic mechanisms contributing to major depression, through a combination of innovative technology development, and systematically establishing causal links between epigenetic targets and disease phenotype. The technologies developed through this proposal will establish a new epigenetic paradigm for drug discovery and have broad impacts for many fields of biomedical research including cancer, diabetes, obesity, and other neurological disorders. THE FOLLOWING RESUME SECTIONS WERE PREPARED BY THE SCIENTIFIC REVIEW OFFICER TO SUMMARIZE THE OUTCOME OF DISCUSSIONS OF THE REVIEW COMMITTEE ON THE FOLLOWING ISSUES. COMMITTEE BUDGET RECOMMENDATIONS: The budget was recommended as requested.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
NIH Director’s Pioneer Award (NDPA) (DP1)
Project #
1DP1MH100706-01
Application #
8351400
Study Section
Special Emphasis Panel (ZGM1-NDPA-A (01))
Program Officer
Beckel-Mitchener, Andrea C
Project Start
2012-09-30
Project End
2016-07-31
Budget Start
2012-09-30
Budget End
2013-07-31
Support Year
1
Fiscal Year
2012
Total Cost
$865,000
Indirect Cost
$365,000
Name
Broad Institute, Inc.
Department
Type
DUNS #
623544785
City
Cambridge
State
MA
Country
United States
Zip Code
02142
Nishimasu, Hiroshi; Shi, Xi; Ishiguro, Soh et al. (2018) Engineered CRISPR-Cas9 nuclease with expanded targeting space. Science 361:1259-1262
Maji, Basudeb; Moore, Christopher L; Zetsche, Bernd et al. (2017) Multidimensional chemical control of CRISPR-Cas9. Nat Chem Biol 13:9-11
Chow, Ryan D; Guzman, Christopher D; Wang, Guangchuan et al. (2017) AAV-mediated direct in vivo CRISPR screen identifies functional suppressors in glioblastoma. Nat Neurosci 20:1329-1341
Gootenberg, Jonathan S; Abudayyeh, Omar O; Lee, Jeong Wook et al. (2017) Nucleic acid detection with CRISPR-Cas13a/C2c2. Science 356:438-442
Smargon, Aaron A; Cox, David B T; Pyzocha, Neena K et al. (2017) Cas13b Is a Type VI-B CRISPR-Associated RNA-Guided RNase Differentially Regulated by Accessory Proteins Csx27 and Csx28. Mol Cell 65:618-630.e7
Yan, Winston X; Mirzazadeh, Reza; Garnerone, Silvano et al. (2017) BLISS is a versatile and quantitative method for genome-wide profiling of DNA double-strand breaks. Nat Commun 8:15058
Nishimasu, Hiroshi; Yamano, Takashi; Gao, Linyi et al. (2017) Structural Basis for the Altered PAM Recognition by Engineered CRISPR-Cpf1. Mol Cell 67:139-147.e2
Shmakov, Sergey; Smargon, Aaron; Scott, David et al. (2017) Diversity and evolution of class 2 CRISPR-Cas systems. Nat Rev Microbiol 15:169-182
Gao, Linyi; Cox, David B T; Yan, Winston X et al. (2017) Engineered Cpf1 variants with altered PAM specificities. Nat Biotechnol 35:789-792
Platt, Randall J; Zhou, Yang; Slaymaker, Ian M et al. (2017) Chd8 Mutation Leads to Autistic-like Behaviors and Impaired Striatal Circuits. Cell Rep 19:335-350

Showing the most recent 10 out of 70 publications